---
title: "Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293969051.md"
description: "Kalaris Therapeutics officer Amy O’Leary Vandekop filed an initial beneficial ownership statement reporting 948 common shares and stock options for 47,415 shares at a price range of USD 6.81-7.31."
datetime: "2026-07-27T20:05:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293969051.md)
  - [en](https://longbridge.com/en/news/293969051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293969051.md)
generator: "portal-rs"
---

# Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement

-   Kalaris Therapeutics officer Amy O’Leary Vandekop reported 948 common shares, plus stock options for 47,415 shares at USD 6.81-7.31. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-318054), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KLRS.US](https://longbridge.com/en/quote/KLRS.US.md)

## Related News & Research

- [Kalaris Therapeutics management to join Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297513633.md)
- [Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement](https://longbridge.com/en/news/294731013.md)
- [Abeona Therapeutics director Mark Alvino disposes of 15,000 common shares worth $87,966](https://longbridge.com/en/news/297702333.md)
- [Palvella Therapeutics director Christopher P. Kiritsy disposes of 313 common shares for $49,141](https://longbridge.com/en/news/298071393.md)
- [Damora Therapeutics grants new hires options for 135,400 shares at $28.18 each](https://longbridge.com/en/news/297910210.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**